Catholic Medical Center (CMC) is a 330-licensed bed (with 258 beds staffed) not-for-profit full-service acute care hospital located in the West Side area of Manchester, New Hampshire, United States. CMC offers medical-surgical care with more than 26 subspecialties, inpatient and outpatient services, diagnostic imaging and a 30-bed 24-hour emergency department. Norris Cotton Cancer Center at CMC offers medical oncology and infusion services..
Background Mitral valve transcatheter edge‐to‐edge repair can be more challenging in noncentral regions of the valve and in anterior or bileaflet lesions. We assess effect of implant location and leaflet lesion location on safety and effectiveness of PASCAL Precision system in degenerative mitral regurgitation (MR). Methods Mitral valve transcatheter edge‐to‐edge repair outcomes in patients with degenerative MR treated with PASCAL Precision system (September 2022–October 2024), from the US STS/ACC TVT (Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy) Registry, were analyzed by implant location (A2P2/non‐A2P2) and leaflet lesion location (anterior/posterior/bileaflet). Procedural, clinical, and echocardiographic outcomes to 30 days were assessed. Results At 30 days, both A2P2 (n=1526) and non‐A2P2 (n=299) groups had low event rates (cardiovascular mortality: 1.1% versus 1.0%, mitral valve reintervention: 0.4% versus 0.0% and single leaflet device attachment: 0.5% versus 0.3%; all P>0.05) and demonstrated significant MR reduction (P<0.001 versus baseline) with no significant difference between groups (P=0.750) (MR ≤2+: 93.4% versus 95.4%; MR ≤1+: 72.0% versus 73.3%). Kansas City Cardiomyopathy Questionnaire Overall Summary scores improved significantly in both groups (∆19.3, ∆17.7 points; P=0.741). The anterior (n=250), posterior (n=902), and bileaflet (n=192) disease groups also had low event rates (cardiovascular mortality: 0.4%, 1.1%, 0.0%; mitral valve reintervention: 0.8%, 0.1%, 0.5%; and single leaflet device attachment: 0.8%, 0.2%, 0.5%; all P>0.05), and demonstrated significant MR reduction (P<0.001 versus baseline) with no significant difference across groups (P=0.459) (MR ≤2+: 94.1%, 93.1%, and 94.5%; MR ≤1+: 79.0%, 69.2%, and 72.4%). All groups experienced significant improvement in Kansas City Cardiomyopathy Questionnaire Overall Summary scores (∆21.4, ∆18.8, ∆12.0 points; P=0.087). Conclusion In real‐world patients with degenerative mitral regurgitation, treatment with the PASCAL Precision system was associated with favorable safety and effectiveness at 30 days, regardless of implant location or leaflet lesion location.
Transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) have transformed the management of severe aortic stenosis across a wide range of patient risk profiles. As populations age and indications extend to lower-risk and younger patients, determining the appropriate role of age in selecting TAVR versus SAVR has become increasingly complex. Current guidelines emphasize individualized decision-making, yet age-based referral patterns remain common in clinical practice. This review examines how age thresholds are applied in contemporary guidance from the United States (US), Europe, and the Asia-Pacific region. Additionally, this review evaluates whether chronological age alone is a defensible basis for referral or treatment selection. This evidence-based narrative review queried PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) from January 1, 2013, through December 31, 2025, using the search terms: ("aortic stenosis" AND ("TAVR" OR "transcatheter aortic valve implantation (TAVI)" OR "SAVR")) AND ("age" OR "appropriateness"). English-language abstracts and full texts were screened in duplicate. Eligible studies included randomized controlled trials, national or continental registries, health economic simulations, and clinical practice guidelines that reported age-stratified outcomes or recommendations. Single-case reports, editorials, and animal studies were excluded. Of the 1628 titles screened, 87 full texts were reviewed, and 45 studies were retained. Across regions, guidelines converge on a core principle: age is informative but insufficient in isolation. U.S. guidance generally favors SAVR in patients younger than 65 years or those with a life expectancy greater than 20 years, and favors transfemoral TAVR in patients older than 80 years or with a life expectancy shorter than 10 years. European guidance typically favors SAVR in patients younger than 75 years and TAVR in those older than 75 years. Meanwhile, Asia-Pacific recommendations adopt a similarly individualized approach but place greater emphasis on bicuspid anatomy, rheumatic disease, local health system infrastructure, and cost. Recent data support a cautious approach in younger patients. In observational U.S. analyses of patients younger than 65 years, TAVR use increased substantially despite guideline preference for surgery, and TAVR was associated with higher long-term mortality or higher pacemaker and readmission burdens in selected cohorts. Contemporary randomized data suggest broadly similar outcomes between TAVR and SAVR in older or intermediate-age populations; however, uncertainty persists in younger low-risk patients, particularly those with bicuspid anatomy and long projected survival. Age-based cutoffs should be interpreted as decision anchors rather than rigid rules. The most defensible framework integrates age with life expectancy, valve durability, anatomy, frailty, comorbidity burden, coronary artery disease, feasibility of future valve-in-valve therapy, and patient preferences within a multidisciplinary heart team. Expansion of TAVR into younger populations should remain measured until more robust long-term durability and lifetime management data become available.
Positive margins after breast-conserving surgery (BCS) require additional surgery, a negative patient experience that also adds costs to care. Pilot trials indicate the Breast Cancer LocatorTM (BCL), a novel supine magnetic resonance imaging–based guidance system, helps surgeons resect cancers with a low positive margin rate (PMR). Our objective was to evaluate BCL noninferiority and superiority compared with wire localization (WL) in reducing the PMR with BCS. Patients with nonpalpable, magnetic resonance imaging–visualized invasive breast cancer or ductal carcinoma in situ undergoing BCS were prospectively randomized to either BCL or WL. In total, 418 randomized patients underwent surgery. The PMR was 14.4
Background Patients who present with ST-elevation myocardial infarction (STEMI) to a hospital without primary percutaneous coronary intervention (PPCI) capability may be transferred for PPCI or receive fibrinolytic therapy, depending on whether the first medical contact to balloon time of ≤120 minutes can be achieved. We hypothesized that travel distance to the percutaneous coronary intervention (PCI) center might impact STEMI outcomes in a rural STEMI system of care. Methods We retrospectively analyzed 6225 consecutive STEMI patients from the Northern New England Cardiovascular Disease Study Group registry from 2018 to 2023. Residential distance to care was calculated by road travel distance between ZIP Code centroids and grouped into quartiles. Patients were categorized by treatment strategy: initial presentation to a PCI center, transfer for PPCI, or pharmacoinvasive PCI. The primary outcome was in-hospital mortality. Multivariable logistic regression evaluated the association between residential distance and treatment strategy with in-hospital mortality. Results The median residential distance to PCI center for STEMI patients in Northern New England was 38.2 miles (IQR, 47.1). Of the overall cohort, 44.4% (median travel distance: 17.2 miles) had index presentation to a PCI hospital, 23.8% (median travel distance: 40.1 miles) underwent interhospital transfer for primary PCI, and 31.9% (median travel distance: 66.5 miles) were transferred for pharmacoinvasive PCI after initial lytic therapy. There was no association between distance to PCI hospital and adjusted in-hospital mortality after STEMI, irrespective of the treatment group. Conclusions In Northern New England with contemporary regional STEMI referral networks, distance to PCI hospital did not impact STEMI mortality despite substantial travel distances for many patients.
e22540 Background: NUT carcinoma (NC) or NUT midline carcinoma is an extremely rare, undifferentiated or a poorly differentiated squamous cell malignancy that can arise anywhere in the body, but often originates along the midline structures (head, neck or lungs). It is characterized by chromosomal rearrangement of NUT gene, commonly BRD3 or BRD4 gene. This fusion oncogene produces abnormal NUT (Nuclear protein in testis) protein causing dysplastic squamous cell proliferation. NC presents at later stages with B-symptoms and symptoms specific to the organ of origin. The purpose of this study is to determine epidemiology and factors affecting survival in NC. Methods: We extracted cases of NUT carcinoma diagnosed after the age of 20 years, using the ICD Code 8023/3, from Surveillance, Epidemiology and End Result database Research Plus Data, 17 Registries, Nov 2023 Sub (2000-2021). The data was stratified based on age, sex, race, laterality, primary site labelled, stage, median household income inflation adjusted to 2022, and treatment modalities used. Survival curves were compared using Log-Rank test (GraphPad Prism). Results: Only 49 cases of NUT carcinoma were found from 2000 to 2021. Of these cases, 69.4% were males and 30.6% were females. Racial distribution in descending order was noted as: White (59.18%) patients followed by Hispanics (20.41%), Asians/Pacific Islanders (16.33%), and Blacks (4.1%). No cases were reported in Alaskans or Native Americans. Over 90% of the cases had positive regional lymph nodes at the time of diagnosis. The median age of diagnosis was 54 years. The overall median of survival (MoS) was 10 months, with a 1-year survival of 0.415 (CI 95%, 0.26-0.563), 3-year survival of 0.29 (CI 95%, 0.14-0.46). The median of survival (MoS) based on age, race, gender, laterality and median household income showed no statistical significance. MoS for primary site was significant for head & neck (14), GI (<1), lungs (8), peritoneum (1.5) and unknown site (undefined, due to no reported death in this category) (p <0.0001). Analysis based on stage revealed higher MoS for localized while lowest MoS for distant disease (p 0.0088). Treatment base survival was calculated as: chemotherapy (14) vs no chemotherapy (1) (p <0.0001), and radiation therapy (14) vs no XRT (2) (p 0.0009). Similarly, survival calculated for surgery was significantly higher than without it (p 0.0173). Conclusions: NUT carcinoma is an ultra-rare malignancy with only 49 cases reported in the past two decades in SEER database. This aggressive neoplasm favoured males and Caucasians race. Overall, better survival outcomes were associated with earlier stages, tumors originating from head & neck or lungs, and management involving either surgery, chemotherapy or radiotherapy. Prognosis was independent of age, gender, race, laterality and income. Further research is warranted to determine the impact of next generation sequencing based immunotherapy on the survival outcomes.